Novo Nordisk has significantly increased the production of its weight loss drug Wegovy, which is in high demand, and is now hoping to have stabilized its supply early next year, the company writes in an update on its website.
Depending on the demand for the drug, production may still be affected by delays for the rest of 2021, before stabilizing in 2022.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.